Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus

Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:FEBS Open Bio
Autori principali: Nishio, Eiji, Hayashi, Takanori, Akaza, Mao, Hisatomi, Yukiko, Hikichi, Masahiro, Fujii, Takuma, Utsumi, Toshiaki, Harada, Nobuhiro, Shimono, Yohei
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530388/
https://ncbi.nlm.nih.gov/pubmed/32810922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12956
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi